Vir Biotechnology (NASDAQ:VIR) shareholders are still up 86% over 3 years despite pulling back 7.9% in the past week – Simply Wall St

One simple way to benefit from the stock market is to buy an index fund. But if you buy good businesses at attractive prices, your portfolio returns could exceed the average market return. For example, the Vir Biotechnology, Inc. (NASDAQ:VIR) share price is up 86% in the last three years, clearly besting the market return of around 21% (not including dividends).

While the stock has fallen 7.9% this week, it’s worth focusing on the longer term and seeing if the stocks historical returns have been driven by the underlying fundamentals.

Check out the opportunities and risks within the US Biotechs industry.

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

During three years of share price growth, Vir Biotechnology moved from a loss to profitability. So we would expect a higher share price over the period.

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

It is of course excellent to see how Vir Biotechnology has grown profits over the years, but the future is more important for shareholders. If you are thinking of buying or selling Vir Biotechnology stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

The last twelve months weren’t great for Vir Biotechnology shares, which performed worse than the market, costing holders 42%. The market shed around 19%, no doubt weighing on the stock price. Fortunately the longer term story is brighter, with total returns averaging about 23% per year over three years. Sometimes when a good quality long term winner has a weak period, it’s turns out to be an opportunity, but you really need to be sure that the quality is there. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we’ve identified 1 warning sign for Vir Biotechnology that you should be aware of.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

What are the risks and opportunities for Vir Biotechnology?

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Source